SEARCH

SEARCH BY CITATION

References

  • Abrams, P., Schulman, C.C. & Vaage, S. (1995). The efficacy and safety of 0.4 mg tamsulosin once daily in symptomatic BPH. Procs. Am. Urol. Assoc., 153, (Suppl.) 274A.
  • Arunlakshana, O. & Schild, H.O. (1959). Some quantitative uses of drug antagonists. Br. J. Pharmacol. Chemother., 14, 4858.
  • Burt, R.P., Chapple, C.R. & Marshall, I. (1995). Evidence for a functional α1A- (α1C)-adrenoceptor mediating contraction of the rat epidiymal vas deferens and an α1B-adrenoceptor mediating contraction of the rat spleen. Br. J. Pharmacol., 115, 467475.
  • Chapple, C.R. (1995). α-Adrenergic blocking drugs in bladder outflow obstruction. What potential has α1-adrenoceptor selectivity. Br. J. Urol., 76, Suppl. 1, 4755.
  • Chess-Williams, R., Chapple, C.R., Verfurth, F., Noble, A.J., Couldwell, C.J. & Michel, M.C. (1996). The effects of SB216469, an antagonist which discriminates between the α1A-adrenoceptor and the human prostatic α1-adrenoceptor. Br. J. Pharmacol., 119, 10931100.
  • Donker, P.J., Ivanovici, F. & Noach, E.L. (1972). Analyses of the urethral pressure profile by means of electromyography and the administration of drugs. Br. J. Urol., 44, 180193.
  • Flavanhan, N.A. & Vanhoutte, P.H. (1986). α1-Adrenoceptor subclassification in vascular smooth muscle. Trends Pharmacol. Sci., 7, 347349.
  • Foglar, R., Shibata, K., Horie, K., Hirasawa, A. & Tsulimo-To, G. (1995). Use of recombinant α1-adrenoceptors to characterise subtype selectivity of drugs for the treatment of prostatic hypertrophy. Eur. J. Pharmacol., 288, 201207.
  • Ford, A.P.D.W., Arredondo, N.F., Blue, D.R., Bonhaus, D.W., Jasper, J., Kava, M.S., Lesnick, J., Pfister, J.R., Shieh, L.A., Vimont, R.L., Williams, T.L., Mcneal, J.E., Stamey, T.A. & Clarke, D.E. (1996a). RS17053 (N-[2-(2-cyclopropyl-methox-yphenoxy)ethyl]-5-chloro-alpha, alpha-dimethyl- 1H-indole-3-et-hanamine hydrochloride), a selective alpha(1A)-adrenoceptor antagonist, displays low affinity for functional alpha 1-adreno-ceptors in human prostate: implications for adrenoceptor classification. Mol. Pharmacol., 49, 209215.
  • Ford, A.P.D.W., Daniels, D.V., Chang, D.J., Diaz, M.R., Gever, J.R., Jasper, J.R., Lesnick, J.D. & Clarke, D.E. (1996b). The putative α1L receptor (AR): a distinct pharmacological state of the α1A-adrenoceptor Br. J. Pharmacol., 118, 29P.
  • Ford, A.P.D.W., Williams, T.J. & Blue, D.R. (1994). α1-Adrenoceptor classification: sharpening Occam's razor. Trends Pharmacol. Sci., 15, 167170.
  • Forray, C, Bard, J.A., Wetzel, J.M., Wetzel, J.M., Chiu, G., Shapiro, E., Tang, R., Lepor, H., Hartig, P.R., Weinshank, R.L., Branchek, T.A. & Gluchowski, C. (1994). The alpha1 adrenergic receptor that mediates smooth muscle contraction in human prostate has the pharmacological properties of a cloned alphalc subtype. Mol. Pharmacol., 45, 703709.
  • Furukawa, K., Chess-Williams, R. & Uchiyama, T. (1996). α1B-adrenoceptor subtype-mediating the phenylephrine-induced contractile response in rabbit corpus cavernosum penis. Jap. J. Pharmacol., 71, 325331.
  • Furukawa, K., Rosario, D.J., Smith, D.J., Chapple, C.R., Uchiyama, T. & Chess-Williams, R. (1995). α1A-Adrenocep-tor mediated contracile responses of the human vas deferens. Br. J. Pharmacol., 116, 16051610.
  • Furuya, S., Kumamoto, Y., Yokoyama, E., Tsukamoto, T., Izumi, T. & Abiko, Y. (1982). Alpha-adrenergic activity and urethral pressure profilometry in prostatic zone in benign prostatic hypertrophy. J. Urol., 128, 836839.
  • Han, C., Hollinger, S., Theroux, T.L., Esbenshade, T.A. & Minneman, K.P. (1995). 3H-Tamsulosin binding to cloned α1 -adrenergic receptor subtypes expressed in human embryonic kidney 293 cells: antagonist potencies & sensitivity to alkylating agents. Pharmacol. Commun., 5, 117126.
  • Hatano, A., Takahashi, H., Tamaki, M., Komeyama, T., Koizumu, T. & Takeda, M. (1994). Pharmacological evidence of distinct α1 adrenoceptor subtypes mediating the contraction of human prostatic urethra and peripheral artery. Br. J. Pharmacol., 113, 723728.
  • Hieble, J.P., Bylund, D.B., Clarke, D.E., Eikenburg, D.C., Langer, S.Z., Lefkowitz, R.J., Minneman, K.P. & Ruffolo, Jr, J.R. (1995). International union of pharmacology X. Recommendation for nomenclature of oci-adrenoceptors: consensus update. Pharmacol. Rev., 47, 267270.
  • Hieble, J.P., Caine, M. & Zalaznik, E. (1985). In vitro characterization of the α adrenoceptors in human prostate. Eur. J. Pharmacol., 107, 111117.
  • Hirasawa, A., Shibata, K., Horie, K., Takei, Y., Oblika, K., Tanaka, T., Muramoto, N., Takagaki, K., Yano, J. & Tsujimoto, G. (1995). Cloning, functional expression and tissue distribution of human alpha1c-adrenoceptor splice variants. FEBS Letts., 363, 256260.
  • Kawabe, K. (1995). Efficacy and safety of tamsulosin in the treatment of benign prostatic hyperplasia. Br. J. Urol., 76, (Suppl. 1), 6367.
  • Kenny, B.A, Chalmers, D.H., Philpott, P.C. & Naylor, A.M. (1995). Characterization of an α1D- adrenoceptor mediating the contractile response of rat aorta to noradrenaline. Br. J. Pharmacol., 115, 981986.
  • Kenny, B.A., Naylor, A.M., Carter, A.J., Read, A.M., Green-Grass, P.M. & Wyllie, M.G. (1994). Effect of alpha1-adrenoceptor antagonists on prostatic pressure and blood pressure in the anaesthetised dog. Urology, 44, 5257.
  • Lepor, H. (1995). Clinical evaluation of tamsulosin, a prostate selective α1c-antagonist. J. Urol., 153, 182.
  • Marshall, I., Burt, R.P. & Chapple, C.R. (1995). Noradrenaline contractions of human prostate mediated by α1A-(α1c)adreno-ceptor subtype. Br. J. Pharmacol., 115, 781786.
  • Michel, M.C., Buscher, R., Kerker, J., Kraneis, H., Erd-Brugger, W. & Brodde, O-E. (1993). α1-Adrenoceptor subtype affinities of drugs for the treatment of prostatic hypertrophy. Naunyn-Schmiedeberg's Arch. Pharmacol., 348, 385395.
  • Michel, M.C. & Insel, P.A. (1994). Comparison of cloned and pharmacologically defined rat tissue alpha1-adrenoceptor subtypes. Naunyn-Schmiedeberg's Arch. Pharmacol., 350, 136142.
  • Muramatsu, I., Ohmura, T., Hashimoto, S. & Oshita, M. (1995). Functional subclassification of vascular α1-adrenocep-tors. Pharmacol. Commun., 6, 2328.
  • Price, D.T., Schwinn, D.A., Lomasney, J.W., Allen, L.F., Caron, M.G. & Lefkowitz, R.J. (1993). Identification, quantification, and localization of mRNA for three distinct α1-adrenergic receptor subtypes in human prostate. J. Urol., 150, 546551.
  • Schalken, J.A, Van Stratum, P., Smit, F., Van Bokhoven, A., Dela Rosette, J., Korstanje, C. & Debruyne, F.M.J. (1994). Differential expression of alpha1-adrenergic receptor subtypes in BPH determined by reverse transcriptase PCR. Soc. Int. Urol. Proc., A648..
  • Schwinn, D., Wilson, K., Page, S., Campbell, S. & Kwatra, M. (1994). Tamsulosin is selective for cloned α1c AR and α1a/d subtypes. Soc. Int. Urol. Proc., A678.
  • Testa, R., Poggesi, E., Taddei, C, Guarnei, L., Ibba, M. & Leonardi, A. (1994a). REC 15/2739, a new α1-antagonist selective for the lower urinary tract: in vitro studies. Neurourol. Urodynam., 13, 473474.
  • Testa, R., Sironi, G., Colombo, D., Greto, L. & Leonardi, A. (1994b). REC 15/2739, a new α1-antagonist selective for the lower urinary tract: in vivo studies. Neurourol. Urodynam., 13, 471473.
  • Vander Graaf, P.H., Welsh, N.J., Shankley, N.P. & Black, J.W. (1994). Evidence for heterogeneity of α1-adrenoceptors in the rat aorta. Br. J. Pharmacol., 110, 124P.
  • Yamada, S., Tanaka, C., Kimura, R. & Kawabe, K. (1994). Alphai-adrenoceptor in human prostate: characterization and binding characteristics of alpha1-antagonists. Life Sci., 54, 18451854.